Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Oncology Market Access Europe – Payer and Industry Perspectives

Product Code:
596200263
Publication Date:
July 2014
Format:
PDF
Pages:
75
Price:
£695

Oncology Market Access Europe – Payer and Industry Perspectives answers your questions:

  • What are payers looking for when making decisions regarding oncology reimbursement?
  • How are HTAs and other challenges affecting market access and what insight do payers offer?
  • How do payer decisions vary from market to market and what factors influence those decisions?
  • What will be the future role of real world data in payer decision-making?
  • What role do risk-sharing schemes, expanded access programmes and other pricing schemes play?
  • What factors should companies take into account when planning market access strategies?
  • Which innovations, such as PD-1 inhibitors, vaccines, personalised medicine and companion diagnostics show the most promise?

Oncology market access faces significant and mounting challenges as payers increase data requirements and financial austerity holds sway over decision-making. As pricing and reimbursement requirements become more stringent, issues of development cost, risk and slow market growth are at the forefront. In order to achieve market access success, companies need to adapt their approach and include health outcomes data to meet payer requirements.

To learn more about the report by viewing sample pages and a list of experts interviewed, click here.

Critical insight

Based on interviews and surveys with experts from the UK, Germany, Italy, France and Spain, FirstWord’s Oncology Market Access Europe – Payer and Industry Perspectives lays out the current – and growing – challenges facing companies in getting drugs to the European market. Filled with compelling insight into the most pressing issues ranging from changing payer data requirements and financial austerity to the adoption of formalised HTA, the report offers critical strategies, knowledge and a roadmap to the future.

A report for the whole industry

The challenges for oncology market access are expected to increase and grow in the near future, making Oncology Market Access Europe – Payer and Industry Perspectives a must-read report not only for those working in market access, brand strategy, business development and licensing, but in biosimilars, payer relationships and drug innovation.

To learn more about the report by viewing sample pages and a list of experts interviewed, click here.

Key benefits, features and Insights

Oncology market access is evolving and requires constant updates to keep abreast of changes. In this report, stakeholders will:

  • Gain insight into both the industry and payer perspectives, with particular reference to the increasing importance of robust clinical health outcomes data
  • Understand the key issues affecting access and how they vary between markets
  • Learn about key strategies for success, such as patient access schemes, price-volume agreements and price capping
  • Identify what effective strategies are used by which companies and why they work
  • Understand why the industry needs to adapt to an evolving and challenging landscape
  • Gain insight into how market access issues are driving decisions around R&D

 

Key features

  • Insight into the innovative strategies being employed to gain market access
  • Overview of new drug approvals and oncology pipeline prospects such as cancer vaccines, niche indications and personalised medicine
  • Examination of the role of HTAs from both payer and industry perspectives
  • Key findings regarding the importance of early inclusion of market access considerations

To learn more about the report by viewing sample pages and a list of experts interviewed, click here.

Key Insights

  • How oncology market access varies from country to country and why
  • Complete overview of current oncology market access trends and challenges
  • The payer perspective on everything from transparency in information to the use of health outcomes data in decision making
  • How payers view the HTA process and its role in the short to medium term

Key experts interviewed

  • UK payer: Deputy Head of Medicines Management for a PCT with regional and local funding and budgetary decision making responsibility
  • German payer: Head of a national budgetary committee with national, regional and local funding and budgetary decision making responsibility
  • Italian payer: Pharmacist involved in purchasing of drugs and devices for hospital and with national, regional and local funding and budgetary decision making responsibility
  • Spanish payer: Professor of health economics and advisor to the Ministry of Health on pricing and reimbursement issues, with national, regional and local funding and budgetary decision making responsibility
  • French payer – Hospital pharmacist involved in buying medical products including drugs and medical devices for a group of nine hospitals with regional and local funding and budgetary decision making responsibility
  • Former oncology marketing manager, BMS
  • Oncology marketing manager, GSK
  • Oncology medical manager, GSK
  • Oncology market access, Pfizer



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved